Canine Transmissible Venereal Tumor
Complete guide to canine transmissible venereal tumor (CTVT) in dogs — symptoms, diagnosis costs, chemotherapy success rates, prognosis.
If your dog has developed a cauliflower-like growth around the genital area, face, or mouth, one condition your veterinarian will want to rule out is canine transmissible venereal tumor (CTVT), also known as infectious sarcoma or Sticker tumor. CTVT is one of the most remarkable cancers in veterinary medicine: it is one of only a handful of known clonally transmissible cancers in nature, meaning the tumor cells themselves are passed directly from dog to dog through physical contact — not inherited through genetics.
CTVT primarily spreads during mating, but it can also transfer through sniffing, licking, or scratching at affected areas. The disease is most common in tropical and subtropical regions with large free-roaming dog populations, though cases appear worldwide. According to the Merck Veterinary Manual, CTVT accounts for a significant percentage of tumors in intact, free-roaming dogs in endemic areas. The good news? It has one of the highest cure rates of any canine cancer when treated properly.
What Is Canine Transmissible Venereal Tumor?
Canine transmissible venereal tumor is a contagious cancer caused by the direct transplantation of living tumor cells from an affected dog to a healthy dog. Unlike most cancers, which develop from a dog's own mutated cells, CTVT involves the physical transfer of an ancient cell line — genetic analysis shows all CTVT cells worldwide descend from a single "founder" dog that lived an estimated 6,000 to 11,000 years ago.
The tumor cells carry their own independent genome (64 chromosomes, compared to the normal canine 78), and they have evolved mechanisms to evade the host dog's immune system during initial establishment. After a period of growth, most dogs' immune systems eventually recognize and begin attacking the tumor — but veterinary treatment dramatically accelerates resolution and prevents spread.
Recognizing the Symptoms of CTVT in Dogs
CTVT tumors have a characteristic appearance that helps distinguish them from other growths, though biopsy confirmation is always necessary. Tumors typically appear as solitary or multiple nodular, cauliflower-like, or ulcerated masses. Below is a symptom checklist organized by disease progression.
| Stage | Symptoms | Notes |
|---|---|---|
| Early (Weeks 1–5) |
|
Often mistaken for a minor wound or irritation; early veterinary evaluation is critical |
| Progressive (Weeks 5–15) |
|
Tumor is actively growing; immune system has not yet mounted effective response |
| Advanced / Metastatic (Rare) |
|
Metastasis occurs in roughly 5% of cases; more common in immunocompromised or very young dogs |
Risk Factors: Which Dogs Are Most Vulnerable to CTVT?
- Intact (unneutered) status: Sexually active dogs have the highest transmission risk
- Free-roaming lifestyle: Dogs with unsupervised outdoor access encounter more affected dogs
- Geographic region: Highest prevalence in tropical/subtropical areas — Southern US, Central and South America, Africa, Asia, Mediterranean regions
- Age: Most common in sexually active dogs aged 2–5 years, though any age is susceptible
- Breed: No strong breed predisposition, but mixed-breed and free-roaming dogs in endemic areas are overrepresented due to exposure frequency
- Immunocompromised status: Dogs on immunosuppressive therapy, with concurrent disease, or very young puppies may develop more aggressive or metastatic forms
- Stray or shelter populations: High-density dog environments facilitate spread
It is important to note that CTVT does not discriminate by breed. Any intact dog with exposure to an affected animal is at risk. However, the combination of intact status and free-roaming behavior accounts for the vast majority of cases seen in clinical practice.
How Veterinarians Diagnose Canine Transmissible Venereal Tumor
If you suspect CTVT, your veterinarian will follow a structured diagnostic process. CTVT can resemble other conditions — including squamous cell carcinoma, mast cell tumors, and infectious granulomas — so confirmation through cytology or histopathology is essential before treatment begins.
- Physical examination — Visual and tactile assessment of the mass; evaluation of regional lymph nodes
- Fine-needle aspiration (FNA) / Impression cytology — Cells are collected from the tumor surface or via needle and examined under a microscope. CTVT cells have a characteristic appearance: round cells with large, round nuclei, prominent nucleoli, and clear intracytoplasmic vacuoles. This test alone often provides a presumptive diagnosis. Estimated cost: $50–$150
- Biopsy and histopathology — If cytology is inconclusive, a tissue sample is sent to a veterinary pathologist for definitive diagnosis. Estimated cost: $150–$400
- Blood work (CBC and chemistry panel) — Assesses overall health, checks for anemia from chronic blood loss, and evaluates organ function before chemotherapy. Estimated cost: $100–$250
- Imaging (radiographs or ultrasound) — Recommended if metastasis is suspected, to evaluate lymph nodes, thorax, and abdomen. Estimated cost: $200–$600 depending on modality
- Staging — Determines whether the tumor is localized (Stage I), involves regional lymph nodes (Stage II), or has metastasized to distant sites (Stage III). Staging directly guides treatment decisions and prognosis.
Total initial diagnostic costs typically range from $300 to $1,200 depending on how extensive the workup needs to be. Most straightforward cases diagnosed via cytology fall in the lower end of that range.
Treatment Options for Canine Transmissible Venereal Tumor
CTVT is one of the most treatment-responsive cancers in veterinary oncology. The following table compares the primary treatment modalities your veterinarian may recommend.
| Treatment | How It Works | Success Rate | Duration | Estimated Cost |
|---|---|---|---|---|
| Vincristine chemotherapy (first-line) | Weekly IV injections of vincristine sulfate, a vinca alkaloid that disrupts tumor cell division | 90–95% complete remission (per Merck Veterinary Manual) | 3–6 weekly sessions (average 4) | $200–$500 per session; total $800–$3,000 |
| Doxorubicin (second-line / vincristine-resistant cases) | IV chemotherapy used when tumors do not respond to vincristine | High response rate in vincristine-resistant cases | Variable; typically 2–4 sessions at 2–3 week intervals | $300–$700 per session |
| Surgical excision | Physical removal of the tumor mass under general anesthesia | High recurrence rate (30–60%) when used alone without chemotherapy | Single procedure; 10–14 day recovery | $500–$2,000 depending on location and size |
| Radiation therapy | Targeted radiation to shrink or eliminate tumors | Effective but rarely needed; reserved for refractory or inoperable cases | Multiple sessions over 2–4 weeks | $2,000–$6,000+ (requires specialized facility) |
| Spontaneous regression | The dog's immune system eventually recognizes and destroys the tumor without intervention | Variable; may take months and tumor can cause significant damage before regressing | 2–7 months (unpredictable) | No treatment cost, but monitoring visits still required |
Vincristine remains the gold standard for CTVT treatment. Most dogs show dramatic tumor shrinkage after just one or two treatments, and the vast majority achieve complete remission within four to six sessions. Side effects of vincristine in dogs are generally mild and may include temporary gastrointestinal upset, decreased appetite, or mild lethargy. Unlike human chemotherapy protocols, vincristine for CTVT rarely causes significant hair loss or severe immunosuppression at the doses used.
Prognosis and Life Expectancy After CTVT Diagnosis
The prognosis for canine transmissible venereal tumor is among the most favorable of any canine cancer. Here is a stage-by-stage breakdown:
| Stage | Description | Expected Outcome | Life Expectancy Impact |
|---|---|---|---|
| Stage I (Localized) | Single tumor at primary site, no lymph node involvement | Excellent — 90–95% complete cure with vincristine; recurrence is rare | Normal life expectancy; no long-term impact |
| Stage II (Regional) | Tumor with regional lymph node involvement | Good to very good — chemotherapy typically resolves both primary and nodal tumors | Normal life expectancy in most cases |
| Stage III (Metastatic) | Distant metastasis to skin, internal organs, or multiple sites | Guarded — more aggressive treatment needed; some cases respond well, others are refractory | Variable; depends on extent of spread and treatment response |
For the vast majority of dogs diagnosed at Stage I or II and treated with vincristine, CTVT is a curable condition with no reduction in life expectancy. Dogs that achieve complete remission develop lasting immunity to reinfection from the same CTVT cell line — though reinfection from a different variant is theoretically possible, it is exceedingly rare.
Home Care and Management During Treatment
While your dog is undergoing chemotherapy for CTVT, supportive home care plays an important role in recovery and comfort.
During Active Treatment
- Monitor the tumor site: Photograph the tumor weekly to track shrinkage. Note any increase in bleeding, discharge, or odor, which could indicate secondary infection.
- Prevent self-trauma: Use an Elizabethan collar (cone) to prevent licking or scratching at the tumor. Licking can cause secondary infection and may theoretically spread cells to the oral cavity.
- Manage discharge: Gently clean the area with a veterinarian-recommended antiseptic wipe or dilute chlorhexidine solution. Use disposable gloves and wash hands thoroughly after contact.
- Strict separation from other dogs: Your dog must have zero physical contact with other dogs throughout treatment and until your veterinarian confirms complete remission. This includes no shared toys, bowls, or bedding.
- Post-chemotherapy precautions: For 48–72 hours after each vincristine dose, your dog's urine and feces may contain trace chemotherapy metabolites. Wear gloves when handling waste, and clean accidents with an enzymatic cleaner. Keep children away from freshly soiled areas.
- Nutrition: Offer a highly digestible, AAFCO-complete diet. If appetite drops after chemotherapy, try warming food slightly or offering small, frequent meals. Report any vomiting or diarrhea lasting more than 24 hours to your vet.
Post-Treatment Monitoring
After achieving remission, your veterinarian will typically schedule a recheck examination at 1 month and 3 months post-treatment. Watch for any new growths, particularly at the original tumor site or in the mouth and nasal area. Although recurrence is uncommon after successful vincristine therapy, any new mass should be evaluated promptly.
Understanding the Full Cost of CTVT Treatment
Budgeting for CTVT treatment requires understanding the full range of potential expenses. Below is a realistic breakdown based on 2026 veterinary pricing across the United States. Costs vary significantly by region, clinic type (general practice vs. specialty oncology center), and disease stage.
| Expense Category | Typical Case (Stage I) | Complex Case (Stage II–III) |
|---|---|---|
| Initial exam and cytology | $100–$250 | $100–$250 |
| Biopsy / histopathology (if needed) | $0–$400 | $150–$400 |
| Blood work (pre-chemotherapy) | $100–$250 | $100–$250 |
| Imaging (radiographs / ultrasound) | $0–$400 | $200–$800 |
| Vincristine chemotherapy (4–6 sessions) | $800–$2,500 | $1,200–$3,500 |
| Supportive medications (antibiotics, pain relief) | $50–$200 | $100–$400 |
| Recheck visits (2–3 post-treatment) | $100–$300 | $150–$500 |
| Estimated Total | $1,150–$3,900 | $2,000–$6,100+ |
For dogs requiring doxorubicin or radiation therapy due to vincristine resistance, costs can escalate to $5,000–$10,000+. Pet insurance that covers cancer treatment can significantly offset these expenses — however, most policies will not cover pre-existing conditions, so enrollment before diagnosis is important.
Prevention Strategies for CTVT
Because CTVT spreads through direct physical contact with tumor cells, prevention focuses on reducing exposure risk:
- Spay or neuter your dog: This is the single most effective preventive measure. Eliminating mating behavior removes the primary transmission route. According to the AVMA, spaying and neutering also provide additional health benefits including reduced risk of reproductive cancers and pyometra.
- Supervise outdoor time: In areas where CTVT is endemic, keep dogs leashed or in secure, fenced areas where they cannot interact with unknown or free-roaming dogs.
- Avoid contact with affected dogs: If you know a dog in your community has been diagnosed with CTVT, ensure complete separation until that dog has been cleared by a veterinarian.
- Prompt veterinary evaluation of any mass: Early detection means smaller tumors, simpler treatment, lower costs, and less risk of spread to other dogs.
- Support community spay/neuter programs: In endemic regions, reducing the population of intact free-roaming dogs is the most impactful public health approach to controlling CTVT.
Contact your veterinarian or an emergency clinic right away if your dog exhibits any of the following:
- Any new growth or mass on the genitals, face, or inside the mouth
- Persistent bloody or foul-smelling discharge from the genital region or nose
- Difficulty urinating or defecating
- Rapidly enlarging mass (noticeable growth over days to a week)
- Lethargy, pale gums, or weakness (signs of anemia from chronic blood loss)
- Known exposure to a dog diagnosed with CTVT — even if no symptoms are visible yet (incubation period is typically 2–12 weeks)
Early evaluation leads to simpler, less expensive, and more successful treatment. Do not wait to see if the growth "goes away on its own."
Frequently Asked Questions About CTVT
Can humans catch CTVT from their dogs?
No. Canine transmissible venereal tumor is species-specific and cannot be transmitted to humans or other animal species. It spreads only between canids (dogs, and rarely foxes and coyotes). You can safely handle your dog during treatment with basic hygiene precautions.
Is CTVT the same as a sexually transmitted infection (STI)?
While CTVT is transmitted during mating, it is not an infection in the traditional sense — it is not caused by a virus, bacterium, or parasite. It is a transmissible cancer, meaning the actual tumor cells are transferred between dogs. The term "venereal tumor" reflects the most common route of transmission, but the disease can also spread through non-sexual contact like sniffing or licking.
Will my dog be immune after recovering from CTVT?
Yes, in most cases. Dogs that successfully clear CTVT — whether through treatment or spontaneous regression — develop a robust immune response that provides long-lasting protection against reinfection from the same CTVT cell line. This immunity has been demonstrated in experimental studies and is a key reason recurrence after successful treatment is rare.
Can CTVT spread to other pets in my household?
CTVT can spread to other dogs through close contact — licking, sniffing, or mating with the affected dog. Cats, birds, and other non-canine pets are not at risk. If you have multiple dogs, separate the affected dog immediately and have all household dogs examined by your veterinarian.
How quickly does CTVT grow?
After transmission, there is typically a latency period of 2 to 12 weeks before a visible tumor appears. Once established, the tumor grows progressively during a 3- to 15-week growth phase. Without treatment, it may eventually regress spontaneously over several months, but this is unpredictable and the tumor can cause significant tissue damage, bleeding, and secondary infection during that time.
Which breeds are most prone to canine transmissible venereal tumor?
CTVT does not have a strong breed predisposition. Any dog can develop CTVT if exposed. However, mixed-breed dogs and breeds common in free-roaming populations in endemic regions (such as pit bull-type dogs, German Shepherds, and local mixed breeds in tropical areas) are overrepresented in case reports simply due to higher exposure rates. Intact, sexually active dogs of any breed are at greatest risk.
What is the life expectancy of a dog with CTVT?
For dogs diagnosed at Stage I or II and treated with vincristine chemotherapy, life expectancy is normal — the disease is cured in 90–95% of cases with no long-term health consequences. Even Stage III cases can have favorable outcomes with aggressive treatment. CTVT is one of the few cancers where the prognosis is genuinely excellent when managed appropriately by a veterinarian.
This article is for informational purposes only and does not replace professional veterinary advice. If you suspect your dog has CTVT or any other health condition, consult your veterinarian for proper diagnosis and treatment. Sources referenced include the Merck Veterinary Manual and the American Veterinary Medical Association (AVMA).
Jonas Cole
All our authors care for dogs every day — read more of their work on the authors page.
